USPTO serial 79334635
OLIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 9, 2024
- Examiner
- CLARKE, NANCY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with OLIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joesph A. R. Gerber
Joesph A. R. Gerber Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietary supplements; nucleic acid sequences for medical purposes; cultures of microorganisms for medical use; biotechnological preparations for medical use, namely, cells, recombinant DNA sequences, synthetic RNA sequences, and oligonucleotides for use in treating and repairing damaged human tissue through tissue nanotransfection (TNT); reagent paper for medical purposes; drugs for medical purposes, namely, cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, metabolic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; synthetic peptides for the treatment of metabolic, ophthalmic, cardiovascular, pulmonary, hepatological, respiratory, neurological diseases and disorders; cardiovascular pharmaceuticals, anti-diabetic pharmaceuticals, antibacterial pharmaceuticals, macular degeneration treatment pharmaceuticals (or ophthalmic pharmaceuticals), hair loss treatment pharmaceuticals, hepatitis treatment pharmaceuticals, respiratory disease treatment pharmaceuticals, neurological disease treatment pharmaceuticals, hepatological disease treatment pharmaceuticals; materials for dental fillings; colostral antibodies for medical purposes, monoclonal antibodies for medical purposes, hybrid antibodies for medical purposes; all the foregoing for human use and excluding goods related to the care and feeding of animals and plants | ACTIVE | — |
| 042 | Product research and development in the field of biotech technology; scientific research in the field of biotechnology, medical research in the field of biotechnology; scientific research and scientific investigations for medical purposes in the field of biomedicine; scientific research consultation and providing scientific research information both of the foregoing in the field of biomedicine; bacteriological research; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; pharmaceutical research services; scientific research in the field of genetics; medical research laboratory services; Scientific research and scientific investigations for medical purposes, both of the foregoing in the fields of medicine, health and pharmacology; medical research; All the above-mentioned services excluding services related to the care and feeding of animals and plants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OliX Pharmaceuticals, Inc.
- Other trademarks owned by OliX Pharmaceuticals, Inc.
- Other trademarks owned by OliX Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named OLIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 4, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 13, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 13, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 9, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 9, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 9, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 29, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 23, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 23, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 10, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 10, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 12, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 6, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 8, 2024 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Jan 8, 2024 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Jan 8, 2024 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Dec 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 27, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 21, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 24, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 24, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 24, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 3, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 2, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 2, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2023 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jan 12, 2023 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Jan 4, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 12, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 12, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 28, 2022 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Oct 1, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Sep 29, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 28, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2022 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Mar 15, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 10, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |